TScan Therapeutics (TCRX) Non-Current Assets (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Non-Current Assets data on file, last reported at $69.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 11.11% year-over-year to $69.2 million in Q1 2026; TTM through Mar 2026 was $292.3 million, a 4.34% decrease from a year earlier, with the FY2025 full-year figure at $71.6 million, down 8.69% from the prior year.
• Non-Current Assets for Q1 2026 stood at $69.2 million, down from $71.6 million in the prior quarter.
• Over the last five years, Non-Current Assets for TCRX reached as high as $78.4 million in Q4 2024 and fell as low as $22.5 million in Q1 2022.
• Historically, Non-Current Assets has averaged $65.8 million across 5 years, with a median of $74.1 million in 2025.
• Across the five-year window, Non-Current Assets soared 233.87% in 2022 and declined 11.11% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $75.0 million in 2022, then increased by 3.93% to $77.9 million in 2023, then increased by 0.62% to $78.4 million in 2024, then dropped by 8.69% to $71.6 million in 2025, then declined by 3.29% to $69.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $69.2 million in Q1 2026, $71.6 million in Q4 2025, and $74.1 million in Q3 2025.